Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2016 07:03 ET | Source: KemPharm

KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate

CORALVILLE, Iowa, Sept. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
September 15, 2016 07:00 ET | Source: KemPharm

KemPharm, Inc. Provides Corporate and Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET KemPharm adjusts product development timelines following full pipeline analysis and positions KP415 and KP201/IR...
September 08, 2016 07:30 ET | Source: KemPharm

KemPharm to Present Data at PAINWeek 2016

CORALVILLE, Iowa, Sept. 08, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
August 10, 2016 07:00 ET | Source: KemPharm

KemPharm, Inc. Reports Second Quarter 2016 Results

Recent Clinical Development & Regulatory Highlights: Completed FDA End of Review meeting for Apadaz™ following receipt of Complete Response LetterReported results from KP511 Phase 1...
August 02, 2016 16:11 ET | Source: KemPharm

KemPharm, Inc. to Report Second Quarter 2016 Results

CORALVILLE, Iowa, Aug. 02, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
July 28, 2016 08:02 ET | Source: KemPharm

KemPharm to Present at Canaccord Genuity 36th Annual Growth Conference

CORALVILLE, Iowa, July 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
July 14, 2016 16:10 ET | Source: KemPharm

KemPharm Completes Key Regulatory Meetings with FDA for KP201/IR and KP415

CORALVILLE, Iowa, July 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
June 28, 2016 16:15 ET | Source: KemPharm

KemPharm’s Prodrug of Hydromorphone, KP511, Demonstrates Comparable Oral Pharmacokinetics to Hydromorphone in Phase 1 Trial

CORALVILLE, Iowa, June 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
June 13, 2016 16:15 ET | Source: KemPharm

FDA Issues Complete Response Letter for Apadaz™ New Drug Application

CORALVILLE, Iowa, June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
June 09, 2016 06:55 ET | Source: KemPharm

KemPharm Files NDA Amendment Request with FDA for Apadaz™

CORALVILLE, Iowa, June 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...